Skip to nav Skip to content

Clinical Trial Search

290 Clinical Trials Found

Clinical Trial 21383

A Prospective, Randomized, Controlled, Open-label, Multicenter Trial to Evaluate Efficacy, Safety and Patient-reported Outcomes of Peptide Receptor Radionuclide Therapy (PRRT) with Lutetium (177Lu) Edotreotide compared to Best Standard of Care in Patients with Well-differentiated Aggressive Grade 2 and Grade 3, Somatostatin Receptor-positive (SSTR+), Neuroendocrine Tumors of GastroEnteric or Pancreatic Origin (COMPOSE)
Disease Site: Other Digestive Organ, Other Endocrine System
PI: Strosberg, Jonathan

Clinical Trial 21860

A Phase 3 Randomized Clinical Study of MK-4280A (coformulated favezelimab [MK-4280] plus pembrolizumab [MK-3475]) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (KEYFORM-008)
Disease Site: Lymphoma
PI: Saeed, Hayder

Clinical Trial 22595

Disease Site: Multiple Myeloma
PI: Paba Prada, Claudia

Clinical Trial 20110

GBM Agile: Global Adaptive Trial Master Protocol
Disease Site: Brain and Nervous System
PI: Grogan, Patrick

Clinical Trial 20831

A Phase 1b/3 Double-Blind, Randomized,Active-Controlled, 3-Stage, Biomarker Adaptive Study of Tazemetostat or Placebo in Combination with Lenalidomide Plus Rituximab in Subjects with Relapsed/Refractory Follicular Lymphoma
Disease Site: Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma
PI: Gaballa, Sameh

Clinical Trial 21024

A Phase IIa Study of Dendritic Cell Vaccines against HER2/HER3 and Pembrolizumab in Patients with Asymptomatic Brain Metastasis from Triple Negative Breast Cancer (TNBC) or HER2+ Breast Cancer (HER2+BC)
Disease Site: Brain and Nervous System
PI: Forsyth, Peter

Clinical Trial 21341

A Phase II Study of Cemiplimab plus Ziv-Aflibercept for Subjects with Metastatic Uveal Melanoma
Disease Site: Eye and Orbit
PI: Tarhini, Ahmad

Clinical Trial 21143

Disease Site: Mycosis Fungoides
PI: Sokol, Lubomir

Clinical Trial 20386

Targeting ODC as an Immunotherapeutic Target in STK11 (LKB1) Pathway-Deficient NSCLC
Disease Site: Lung
PI: Gray, Jhanelle

Clinical Trial 21707

A Proof of Concept Study of TBio-4101 (an Autologous selected and expanded tumor infiltrating lymphocyte [TIL] therapy) Using Short-Term Cultured, Selected Autologous TIL following a Lymphodepleting Chemotherapy Regimen and Followed by IL-2 for Patients with Relapsed or Refractory Solid Tumors (Phase 1)
Disease Site: Colon, Melanoma, skin, Rectum
PI: Sarnaik, Amod

Clinical Trial 21887

A Phase 1/2 Study of Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes
Disease Site: Leukemia, other
PI: Padron, Eric

Clinical Trial 22071

Melanoma Margins Trial (MelMarT-II): A Phase III, multi-centre, multi-national randomised control trial investigating 1cm v 2cm wide excision margins for primary cutaneous melanoma
Disease Site: Other
PI: Zager, Jonathan